Safety Profile of CAP7.1 Obtained During Phase I Trial in Adult Patients with Refractory Malignancies
January 2016
in “
Refubium (Universitätsbibliothek der Freien Universität Berlin)
”
Studysummary In this study, the safety profile of the prodrug CAP7.1 was found to be similar to other topoisomerase inhibitors, with myelosuppression as the main dose-limiting toxicity.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on refubium.fu-berlin.de →